- Home
- MESO vs TPB Comparison
MESO vs TPB Comparison
Compare MESO & TPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- TPB
- Stock Information
- Founded
- MESO 2004
- TPB 1988
- Country
- MESO Australia
- TPB United States
- Employees
- MESO N/A
- TPB N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- TPB Tobacco
- Sector
- MESO Health Care
- TPB Consumer Discretionary
- Exchange
- MESO Nasdaq
- TPB Nasdaq
- Market Cap
- MESO 1.4B
- TPB 1.2B
- IPO Year
- MESO N/A
- TPB 2016
- Fundamental
- Price
- MESO $10.64
- TPB $74.25
- Analyst Decision
- MESO Buy
- TPB Strong Buy
- Analyst Count
- MESO 4
- TPB 4
- Target Price
- MESO $18.00
- TPB $73.75
- AVG Volume (30 Days)
- MESO 226.6K
- TPB 246.5K
- Earning Date
- MESO 02-26-2025
- TPB 05-07-2025
- Dividend Yield
- MESO N/A
- TPB 0.40%
- EPS Growth
- MESO N/A
- TPB N/A
- EPS
- MESO N/A
- TPB N/A
- Revenue
- MESO $5,670,000.00
- TPB $384,032,000.00
- Revenue This Year
- MESO $178.09
- TPB $21.66
- Revenue Next Year
- MESO $305.06
- TPB $9.08
- P/E Ratio
- MESO N/A
- TPB $31.53
- Revenue Growth
- MESO N/A
- TPB 24.54
- 52 Week Low
- MESO $5.78
- TPB $30.62
- 52 Week High
- MESO $22.00
- TPB $81.05
- Technical
- Relative Strength Index (RSI)
- MESO 40.85
- TPB 62.94
- Support Level
- MESO $10.60
- TPB $70.33
- Resistance Level
- MESO $11.26
- TPB $74.15
- Average True Range (ATR)
- MESO 0.41
- TPB 2.28
- MACD
- MESO -0.06
- TPB -0.32
- Stochastic Oscillator
- MESO 12.00
- TPB 66.81
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About TPB Turning Point Brands Inc.
Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in three segments namely Zig-Zag products; Stoker's products and NewGen products. The company generates maximum revenue from the Zig-Zag products segment.